PGNX

Progenics Pharmaceuticals Stock Price

4.10
0.00 (0.0%)
4.10
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Progenics Pharmaceuticals Inc PGNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 4.10 19:00:00
Open Price Low Price High Price Close Price Previous Close
4.10 4.10
Bid Price Ask Price Spread News
4.28 4.35 0.07 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 4.10 USD

Progenics Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 355.05M 86.60M 62.11M $ 34.99M $ - -0.80 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Progenics Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PGNX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months4.304.83013.864.333,017,345-0.20-4.65%
1 Year5.286.701.894.271,063,296-1.18-22.35%
3 Years5.759.41721.895.651,171,472-1.65-28.7%
5 Years6.7411.721.896.121,123,956-2.64-39.17%

Progenics Pharmaceuticals Description

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.


Your Recent History
NASDAQ
PGNX
Progenics ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.